BMS-1166
Catalog No: 2073102
CAS Number: 1818314-88-3
Purity: 98% Min.
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM, antagonizing the inhibition of PD-1/PD-L1 on T cell activation.
For research use only. We do not sell to patients.
Chemical Information
| Name | BMS-1166 |
|---|---|
| Iupac Chemical Name | (2R,4R)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic acid |
| Synonyms | BMS1166 ; BMS 1166 ; BMS-1166 |
| Molecular Formula | C36H33ClN2O7 |
| Molecular Weight | 641.12 |
| Smile | O=C([C@@H]1N(CC2=CC(Cl)=C(OCC3=CC=CC(C4=CC=C5OCCOC5=C4)=C3C)C=C2OCC6=CC=CC(C#N)=C6)C[C@H](O)C1)O |
| InChiKey | QBXVXKRWOVBUDB-GRKNLSHJSA-N |
| InChi | InChI=1S/C36H33ClN2O7/c1-22-26(6-3-7-29(22)25-8-9-32-35(14-25)44-11-10-43-32)21-46-34-16-33(45-20-24-5-2-4-23(12-24)17-38)27(13-30(34)37)18-39-19-28(40)15-31(39)36(41)42/h2-9,12-14,16,28,31,40H,10-11,15,18-21H2,1H3,(H,41,42)/t28-,31-/m1/s1 |
| CAS Number | 1818314-88-3 |
| Related CAS | 1818314-88-3 |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Skalniak L, Zak KM, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, Pyrc K, Dömling A, Dubin G, Holak TA. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017 Aug 7;8(42):72167-72181. doi: 10.18632/oncotarget.20050. eCollection 2017 Sep 22. PubMed PMID: 29069777; PubMed Central PMCID: PMC5641120.
Chemical Structure
